Clinical Trials

19 enrolled 10 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT05070403 2026-04-01

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

25 enrolled

Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms

NCT01783587 2026-03-25

Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer

29 enrolled

Phase 2/3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT02438722 2026-02-06

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

174 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT02979977 2026-02-04

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

50 enrolled 14 charts

Squamous Cell Cancers of the Head and Neck

NCT06302621 2026-01-15

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Phase 1 Recruiting

70 enrolled

Neoplasm Metastasis, Cholangiocarcinoma

NCT01856478 2026-01-12

LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Phase 3 Completed

340 enrolled 23 charts

Head and Neck Neoplasms

NCT06494189 2025-12-29

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

9 enrolled

Head and Neck Neoplasms

NCT07040956 2025-12-29

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

98 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06085755 2025-12-15

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

61 enrolled

Stomach Neoplasms

NCT07271446 2025-12-09

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

8 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06753747 2025-12-03

A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

45 enrolled

Esophageal Neoplasms

NCT06804850 2025-11-19

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Phase 2 Withdrawn

Phase 1 Not yet recruiting

Head and Neck Neoplasms

NCT06897735 2025-11-18

EDDIS-a1

24 enrolled

DermatologicHead & NeckThoracic

Lung Neoplasms, Melanoma, Mouth Neoplasms

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase 1 Active not recruiting

610 enrolled

Other solid neoplasmSarcoma

Advanced Solid Tumors

NCT04497584 2025-10-01

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

12 enrolled

Phase 1/2 Active not recruiting

Advanced Squamous Non Small Cell Lung Cancer

NCT03785249 2025-09-30

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

731 enrolled 3 FDA

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05588609 2025-09-18

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Phase 2 Terminated

13 enrolled

GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

NCT04439136 2025-09-05

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

LymphoidOther hematologic neoplasmPlasma cell

40 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT00716417 2025-08-05

Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours

47 enrolled 18 charts

Neoplasms

NCT05517330 2025-07-31

neoCHANCE-1

23 enrolled

Head and Neck Neoplasms

NCT06709859 2025-07-17

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02191891 2025-06-25

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

32 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT07010120 2025-06-13

A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

29 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05516589 2025-05-22

neoCHANCE-2

40 enrolled

Phase EARLY_PHASE1 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02122172 2025-04-25

Afatinib in Advanced Refractory Urothelial Cancer

Phase 2 Terminated

32 enrolled 14 charts

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT05432518 2025-04-25

Pilot Trial for Treatment of Recurrent Glioblastoma

10 enrolled

CNS

Glioblastoma, Recurrence

NCT01853826 2025-04-11

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Phase 3 Completed

481 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT05298176 2025-03-28

COMBINATION

5 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02597946 2025-02-19

Afatinib in NSCLC With HER2 Mutation

18 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT05215548 2025-02-19

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

100 enrolled

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT03083678 2025-02-13

Afatinib in Locally Advanced and Metastatic Chordoma

43 enrolled

Sarcoma

Chordoma

NCT00748709 2025-02-11

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Phase 2 Terminated

20 enrolled 11 charts

Neoplasms

NCT01649271 2025-02-11

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

13 enrolled 11 charts

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT00950742 2025-02-10

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

18 enrolled 14 charts

Breast

Breast Neoplasms

NCT01214616 2025-02-07

BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours

17 enrolled 15 charts

Neoplasms

NCT02171650 2025-01-23

BIBW 2992 in Patients With Advanced Solid Tumors

7 enrolled

Neoplasms

NCT06071013 2025-01-23

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

20 enrolled

Phase 3 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung

NCT06759857 2025-01-06

FHND9041

350 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06741982 2024-12-19

A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

Phase 1 Recruiting

21 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT01553942 2024-11-20

Afatinib With CT and RT for EGFR-Mutant NSCLC

19 enrolled

Lung Neoplasms

NCT06648096 2024-11-20

AFAN

Classical hematologyHead & Neck

25 enrolled

Squamous Cell Carcinoma of Head and Neck, Fanconi Anemia

NCT02364609 2024-10-16

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

11 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT04183712 2024-10-16

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

102 enrolled

Gallbladder Neoplasms

NCT04839471 2024-07-08

BEAR

49 enrolled

Esophageal Squamous Cell Carcinoma

NCT06486142 2024-07-03

ERIS

Phase 3 Recruiting

200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04410653 2024-04-05

Afatinib in Advanced NRG1-Rearranged Malignancies

3 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Neoplasm Metastasis

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01542437 2024-02-06

NSCLC

66 enrolled